key: cord-0898531-yo4i25eg
authors: Harder, Thomas; Koch, Judith; Vygen-Bonnet, Sabine; Külper-Schiek, Wiebe; Pilic, Antonia; Reda, Sarah; Scholz, Stefan; Wichmann, Ole
title: Authors’ response: Efficacy and effectiveness of COVID-19 vaccines against SARS-CoV-2 infection: More data on asymptomatic SARS-CoV-2 infection
date: 2021-09-02
journal: Euro Surveill
DOI: 10.2807/1560-7917.es.2021.26.35.2100832
sha: 7f4d12ece83896b6a75896f5a288b5fbc832b042
doc_id: 898531
cord_uid: yo4i25eg

nan

In the post-hoc analysis of the Vaxzevria (ChAdOx1-S, AstraZeneca, Cambridge, United Kingdom) licensure trial by Emary et al. [2] , the secondary outcome was named 'asymptomatic infections and infection with unknown symptoms'. Since the outcome description was imprecise, we decided to exclude these data from our report. We agree with the authors of the letter that because of wide and overlapping confidence intervals, the relevance of Emary et al.'s findings is unclear.

Dagan et al. [3] reported a supplementary analysis that included cases without documented symptoms. We decided not to take these results into account since the authors of this paper themselves recognised that their approach is 'an imperfect proxy for asymptomatic infections (since mild symptoms may not be documented)'.

We agree with the authors of the letter that documents submitted to regulatory authorities are valuable sources of information until formal publications are available. In fact, we used the European Medicines Agency (EMA) report on the Janssen COVID-19 vaccine (Janssen-Cilag International, Beerse, Belgium) because of the lack of published evidence on this particular vaccine. As suggested by the authors, we will consider this approach in future updates of this living systematic review also for other vaccines.

Finally, we are also in agreement that the widespread circulation of the SARS-CoV-2 Delta variant (Phylogenetic Assignment of Named Global Outbreak (Pango) lineage designation B.1.617.2) calls for an update of this living systematic review. We are currently in the process of summarising data on the vaccine effectiveness against this particular variant and hope to make them publicly available soon.

Efficacy and effectiveness of COVID-19 vaccines against SARS-CoV-2 infection: interim results of a living systematic review

Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial

BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting

WKS and TH drafted the manuscript. All other authors revised the manuscript.

None declared.